Theranostics 2020; 10(3): 1281-1295. doi: 10.7150/thno.40291

Research Paper

Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment

Weijie Ma1*, Daoming Zhu2*, Jinghua Li1*, Xi Chen1, Wei Xie2, Xiang Jiang1, Long Wu1, Ganggang Wang1, Yusha Xiao1, Zhitsu Liu1, Fubing Wang4, Andrew Li5, Dan Shao3,6, Wenfei Dong3, Wei Liu2*, Yufeng Yuan1*

1. Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
2. Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan, 430072, China.
3. Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, Jiangsu 215163, China.
4. Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
5. Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA.
6. Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.

*These authors contributed equally to this work.

Corresponding authors: Yufeng Yuan. E-mail: yuanyif1971@whu.edu.cn; Wei Liu. E-mail: wliu@whu.edu.cn; Wenfei Dong. E-mail: wenfeidong@126.com

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.09.14; Accepted: 2019.10.29; Published: 2020.01.01

Abstract

Rationale: Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in the world. Apart from traditional surgical resection, radiotherapy, and chemotherapy, more recent techniques such as nano-photothermal therapy and biotherapy are gradually being adopted for the treatment of HCC. This project intends to combine the advantages of nanoscale drug delivery systems with the targeting ability of CAR-T cells.

Method: Based on cell membrane-coated nanoparticles and cell membrane-targeting modifications, a novel nanomaterial was prepared by coating CAR-T cell membranes specifically recognizing GPC3+ HCC cells onto mesoporous silica containing IR780 nanoparticles. Subsequently, the physical properties were characterized, and the in vitro and in vivo targeting abilities of this nanoparticle were verified.

Results: CAR-T cells were constructed which could recognize GPC3 expressed on the cell surface of HCC cells. Then the isolated CAR-T cell membrane was successfully coated on the IR780 loaded mesoporous silica materials, as verified by transmission electron microscopy. The superior targeting ability of CAR-T cell membrane coated nanoparticles compared to IR780 loaded mesoporous silica nanoparticles was verified, both in vitro and in vivo.

Conclusion: This new nanomaterial exhibits photothermal antitumor abilities along with enhanced targeting abilities, suggesting a promising strategy for the treatment of HCC.

Key words: Nanoparticles; chimeric antigen receptor T cell; cell membrane coating technique; photothermal therapy; hepatocellular carcinoma.

Introduction

Hepatocellular carcinoma (HCC) is a solid tumor that is the third most frequent cause of cancer death worldwide [1]. Although the treatment of HCC has made some progress in recent years, the incidence of
local recurrence and distant metastasis is still high, and the poor prognosis of liver cancer patients has not improved [2]. It is impossible to eradicate the residual tumor cells in the circulation with local treatment such as surgery and ablation therapy, and the systemic treatment methods such as chemotherapy are affected by factors such as low sensitivity of liver cancer cells [3, 4].

Recently, intelligent nanoparticles have been developed successfully, with biomimetic cell membrane-based drug delivery systems contributing to progress [5, 6]. The main synthetic strategies require tedious chemical synthesis and optimization especially when trying to integrate multiple functional modalities into one single nanoparticle. Besides, compromised biocompatibility, and accelerated blood clearance (ABC) have also been observed for poly(ethylene glycol) (PEG) which was previously believed to be inert [7]. Cell membrane-coating of nanoparticles, taking advantage of the excellent biocompatibility and versatile functionality of cell membranes can significantly promote the stability of nanoparticles in physiological conditions, resulting in less leakage of drugs [7, 8]. In addition, nanoparticles can exhibit excellent tumor targeting capabilities from membrane coating and subsequent modifications, such as platelet-leukocyte hybrid membrane, erythrocyte membrane and so on [5, 9-17].

Chimeric antigen receptors (CARs) provide T cell populations with defined antigen specificities which target tumors, regardless of the natural T cell receptor. CAR T cells can specifically recognize tumor-associated antigen and eliminate tumor cells by single-chain variable region (ScFv) which derived from monoclonal antibody heavy and light chains and expressed on the cell membrane of CAR-T cells, in a non–major histocompatibility complex-restricted manner. Recent successes in chimeric antigen receptor (CAR) T cell immunotherapy for CD19-positive hematological malignancies have highlighted its potential for treating solid tumors [18-20]. However, this remarkable therapeutic effect was not observed, when CAR-T cell treatment was used in solid tumors, due to certain barriers [21-23]. Aside from proper screening of tumor antigens, long-term persistence of CAR-T cells and efficient trafficking of CAR-T cells from peripheral blood circulation to tumor sites are also essential.

Thus, it is conceivable to combine cell membrane coating nanotechnology with CAR-T therapy to treat solid tumors, due to the high tumor specificity of CAR-T cells and the advantage of cell membrane-camouflaged nanoparticles in drug delivery. In this study, CAR-T membrane-coated nanoparticles were constructed for highly specific therapy for HCC (Figure 1). Glypican-3 (GPC3), a 580-AA heparin sulfate proteoglycan, is expressed in 75 % of HCC samples, but not in healthy liver or other normal tissues [24]. Based on this fact, CAR-T cells capable of recognizing GPC3 on the cell membrane of HCC cells have been developed in recent years, which are cytotoxic to GPC3+ HCC cells [25, 26]. In this study, GPC3 targeting CAR-T cells were first used to prepare CAR-T membranes (CMs). Near-infrared (NIR) dye IR780, a biodegradable photothermal and imaging agent, was then loaded in mesoporous silica nanoparticles (MSNs) to form a biodegradable core. The IR780 dye can produce fluorescence and heat under laser irradiation, and the latter effect can be employed for photothermal therapy [27, 28].

Using MSNs for drug delivery is ideal due to their tunable size, good biocompatibility, lack of toxicity, tunable pore sizes (2-20 nm), and enhanced drug-loading capacity [29-31]. Taking these factors into consideration, IR780-loaded MSNs (IMs) were used in this paper for photothermal therapy to treat HCC. The IMs were coated with a layer of prefabricated CAR-T membranes using an extrusion method to fabricate...
tumor specific CAR-T Cell membrane-coated nanoparticles (CIMs). CIMs demonstrated enhanced tumor targeting and anti-tumor capabilities in vitro and vivo. This targeted nano-system has made significant steps toward further improving nanoparticle functionality in tumor targeted therapy.

**Materials and Methods**

**Materials**

The MSNs used in this study were obtained from Shanghai Carboxyl Bio-pharmaceutical Technology Co., Ltd. (China). Both IR780 and DAPI were obtained from Wuhan Myhalic Biotechnology Co., Ltd. (China). SDS-polyacrylamide gel and buffer were purchased from Epizyme Scientific (Shanghai, China). All aqueous solutions were prepared using deionized (DI) water. Fluorescein diacetate (FDA), propidium iodide (PI) and cell counting kit-8 (CCK-8) were obtained from Sigma-Aldrich (USA). Other solvents used in this study were purchased from Aladdin-Reagent (Shanghai, China) and Sinopharm Chemical Reagent (Shanghai, China).

**Cell lines and culture**

Human HCC cell lines Huh-7 and SK-HEP-1, as well as L02 immortalized human hepatic cell line were purchased from the Cell Bank of Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10 % FBS at 37 °C in a 5 % CO2 incubator.

**GPC3-CARs vectors and lentivirus production**

The extracellular fragment was composed of GPC3-specific ScFv from GC33 [32], linked to the human CD8α hinge and CD28 transmembrane domain. Intracellular signaling domains included the CD28 cytoplasmic domain and \( \text{CD3}\zeta \) molecule. All components were cloned into the second-generation non-self-inactivating SFFV promoter-based lentiviral expression vector pHR. The subsequent production and concentration quantification of lentivirus were completed by Qilu Cell Therapy Technology Co., Ltd. (Shandong, China).

**Isolation, activation, transduction, and culture of T cells**

The primary human T cells were enriched with the RosetteSep kit (Stem Cells Technology, Canada) by negative selection of unwanted cells from peripheral blood mononuclear cells (PBMCs) of healthy donors who provided signed consent. Subsequently, the cells were cultured and anti-CD3/anti-CD28 antibodies (ImmunoCult™ Human CD3/CD28 T Cell Activator, Stem Cells Technology, Canada) were added into the T cell culture medium (RPMI 1640, 10 % FBS, 1 % MEM NAA, 50 μM 2-mercaptoethanol, 300 IU/mL rhIL2) to activate primary T cells at day 0 for 24 h. Then, the T cells were transduced with GPC3-CAR lentivirus at a multiplicity of infection (MOI) of 10 with 4 μg/mL polybrene (Santa Cruz Biotechnology, USA). These genetically modified CAR-T cells were used for subsequent assays after proliferation. The expression of GPC3-CAR was analyzed by Fluorescein (FITC) AffiniPure Goat Anti-Mouse IgG, F(ab')2 fragment specific (Jackson ImmunoResearch, USA). The CD4+/CD8+ T cell population of T cells and CAR-T cells were identified by flow cytometry using APC anti-Human CD3, PE anti-Human CD4 and FITC anti-Human CD8 antibodies (BD, USA). The CellTrace™ CFSE Cell Proliferation Kit (Invitrogen, USA) was also used to test the cell proliferation disparity between CAR-T cells and T cells.

**Western blot, immunohistochemistry, immunofluorescence and cytotoxicity assay**

The expression of GPC3 in Huh7, SK-HEP-1 and L02 cells was detected by western blot, immunohistochemistry and immunofluorescence assays with anti-Glypican 3 antibody (Abcam, USA). The cytotoxicity of GPC3-CAR T cells towards GPC3 overexpressed HCC cells in vitro was measured by lactate dehydrogenase (LDH) assay using the CytoTox 96 nonradioactive cytotoxicity kit (Promega, USA). The corrected values were used in the following formula to compute percent cytotoxicity:

\[ \text{Cytotoxicity\%} = \frac{\text{Experimental} – \text{Effector Spontaneous} – \text{Target Spontaneous}}{\text{Target Maximum} – \text{Target Spontaneous}} \times 100\% \]

**CAR-T and T membrane isolation**

To acquire the cell membranes for nanoparticle coating, T cells and CAR-T cells were washed by PBS twice and then harvested. The cells were suspended in hypotonic lysing buffer consisting of 20 mM Tris-HCl, 10 mM KCl, 2 mM MgCl2, and 1 EDTA-free mini protease inhibitor tablet per 10 mL of solution and disrupted using a dounce homogenizer with a tightfitting pestle. The entire solution was subjected to 20 passes before spinning down at 3,200 g for 5 min. The supernatant was saved, while the pellet was resuspended in hypotonic lysing buffer and subjected to another 20 passes and spun down again. The supernatants were pooled and centrifuged at 20,000 g for 30 min, after which the pellet was discarded and the supernatant was centrifuged again at 80,000 g for 1.5 h using an ultra-speed centrifuge (LE-80K, Beckman Coulter, USA). The pellet containing the plasma membrane material was then washed once...
with 10 mM Tris-HCl and 1 mM EDTA and collected. Then, CAR-T vesicles (CVs) and T cell vesicles (TVs) were obtained by physically extruding the pellet for 11 passes through a 400-nm polycarbonate porous membrane on a mini extruder (Avanti Polar Lipids, USA).

**Preparation of cell membrane coated nanoparticles**

To construct IR780-loaded MSNs (IMs), 5 mg of IR780 was dissolved in 1 mL of dimethylsulfoxide (DMSO), and then the solution was added to 4 mL of PBS solution with gentle stirring. The mixture was added dropwise to 10 mL of distilled water containing 10 mg MSNs, and stirred at room temperature overnight to reach equilibrium. The IMs were pelleted by centrifuging at 8000 rpm for 10 min, and washed with distilled water to remove free IR780. CIMs and TIMs (T cell membranes coated IMs) were produced as previously reported [11]. Briefly, the collected CVs and TVs were mixed with IMs with sonication. The mixture was subsequently extruded 11 times through a 200 nm polycarbonate porous membrane using an Avanti mini extruder, and then excess vesicles were removed by centrifugation.

**Characterization of cell membrane coated nanoparticles**

The particle size and zeta potential of IMs, CAR-T membrane-derived vesicles (CVs), and CIMs were measured by the Malvern Zetasizer ZEN3690 analyzer (Malvern, UK). Transmission electron microscopy (JEM-2010 ES500W, Japan) was used to examine the surface morphologies of the IMs and CIMs, and cell membrane proteins were further examined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein concentrations of the IMs, T membrane-derived vesicles cell vesicles (TVs), CVs, TIMs and CIMs were quantified with the BCA assay kit (Beyotime Biotechnology, China). After being denatured, 10 μg of each specimen was added into a 10 % SDS-polyacrylamide gel, ran at 80 V for 2 h, and then stained with Coomassie blue (Beyotime Biotechnology, China). Subsequently, the gel was washed by deionized water and imaged. Western blot was also performed to show the successful construction of each membrane coated nanoparticles with AffiniPure Goat Anti-Mouse IgG, F(ab’)2 Fragment Specific (Jackson ImmunoResearch, USA).

The concentration of IR780 in CIMs was measured by UV/vis spectrophotometer (Lambda 25, PerkinElmer, USA) based on a standard curve. The drug loading content (DLC) and drug loading efficiency (DLE) of IR780 were calculated as follows:

\[ \text{DLE} = \frac{\text{weight of drug-loaded nanoparticles} \times 100 \%}{\text{weight of feeding IR780}} \]

**Photothermal Conversion Efficiency**

The photothermal conversion efficiency is calculated using Equation:

\[ \eta = \frac{hS(T_{\text{max}} - T_{\text{surr}}) - Q_0}{I(1 - 10^{-\lambda\alpha})} \]

Where \( h \) is the heat transfer coefficient, \( S \) is the surface of the container; \( T_{\text{max}} \) and \( T_{\text{surr}} \) were the equilibrium temperature and ambient temperature, respectively. \( Q_0 \) is the heat associated with the light absorption of the solvent, \( A_\lambda \) is the absorbance of CIMs nanoparticles at 808 nm, and \( I \) is the laser power density. According to the above equation, the \( \eta \) value of CIMs nanoparticles was determined to be about 22.2%.

**Investigation of IR780 release and degradation in vitro**

The IR780 release from different formulations including the IMS, TIMs and CIMs was determined in PBS at 37 °C. At predetermined time intervals, 100 μL of PBS was taken out from the suspension and replaced with an equal volume of fresh PBS. The released IR780 was obtained by centrifugation, and the R780 concentration was measured using UV–vis spectrometer. A certain amount of CIMs (containing 20 μg/mL IR780) were irradiated with NIR irradiation at 0.6 W/cm² for 5 min. Changes in the absorbance and color of the CIMs dispersions were recorded.

**In vitro targeting ability and biocompatibility of CIMs**

To test the targeting ability of the IR780-loaded formulations, 1×10⁵ Huh-7 cells were cultured in 24-well plates, and treated with PBS, IR780, IMS, TIMs and CIMs (containing 50 μg/mL IR780). After 0.5 h
incubation at 37 °C, the treated 24-well plates were washed by PBS, and the cells were stained with DAPI, washed with PBS, and imaged by a confocal laser scanning microscope (CLSM; IX81, Olympus, Japan). The mean fluorescence intensity (MFI) of each group was quantified by a flow cytometer. In addition, the targeting ability of CIMs for different cell lines was evaluated. Briefly, 1×10^5 Huh-7 cells and SK-HEP-1 were cultured in 24-well plates and treated with CIMs (containing 50 µg/mL IR780). After 0.5 h incubation at 37 °C, the treated 24-well plates were washed by PBS, and the cells were stained with DAPI, washed with PBS, and imaged by a confocal laser scanning microscope (CLSM; IX81, Olympus, Japan). To further investigate the targeting ability of particles, the phagocytosis of IR780 by cancer cells was measured at different time points. Again, 1×10^5 Huh-7 cells were cultured in 24-well plates, and treated with IMs, TIMs and CIMs (containing 50 µg/mL IR780). After 1 h incubation at 37 °C, the treated 24-well plates were washed by PBS. To quantify IR780 uptake, the cells were harvested in 1 ml PBS and the IR780 amount in each group was measured by a UV–vis spectrometer. Phagocytosis at 2, 4, 8, 16, and 24 hours was measured by the same method. For the test on GPC3 overexpressed SK-HEP-1 cells, please see details in the Supplementary.

Biocompatibility was evaluated with the normal L02 liver cells. Cells were first cultured into a 24-well plate at a density of 1×10^5 cells/well for 24 h. Various concentrations (0.50, 1.00, and 2.00 mg/mL) of CIMs were added into the cells, respectively, and maintained for 24 h at 37 °C in 5 % CO₂. The viability of nanoparticle treated L02 cells was investigated using the Annexin V-FITC/PI Apoptosis Kit (Multi Sciences, China) following the standard instructions, and quantified by a flow cytometer. The biocompatibility of normal cells under illumination was also verified. Cells were first cultured into a 24-well plate at a density of 1×10^5 cells/well for 24 h. Various concentrations (0.50, 1.00, and 2.00 mg/mL) of CIMs were added into the cells, respectively. After 24 h, the treated 24-well plates were washed by PBS and then exposed to 808 nm wavelength laser irradiation (0.6 W/cm^2) for 5 min. The viability of L02 cells was investigated using the Annexin V-FITC/PI Apoptosis Kit (Multi Sciences, China) following the standard instructions, and quantified by a flow cytometer.

**In vitro phototherapy**

The cytotoxicity of photothermal ablation for each group of nanoparticles was evaluated by Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay. Then, 8×10^3 Huh-7 cells per well were seeded in 96-well plates, and cultured. After 24 h, the cells were treated with the following 6 groups (each group included 3 wells): (1) Control (PBS) (2) IMs (3) CIMs (4) IMs+NIR (5) TIMs+NIR (6) CIMs+NIR. The IR780 concentration was 50 µg/ml in groups 2, 3, 4, 5 and 6. After 2 h incubation, the culture media was refreshed to eliminate the suspended nanoparticles. Then, the cells in groups 4, 5 and 6 were irradiated by an 808 nm laser (0.6 W/cm^2, 5 min). After treatment, CCK-8 solution was added as per instructions, and the cells were incubated for another 4 h. The cytotoxicity was calculated by dividing the optical density (OD) values of treated groups (T) by the OD values of the control (C) (T/C × 100 %).

Furthermore, Huh-7 cells were seeded in 96-well plates at a density of 5×10^5 cells per well and incubated for 24 h. Then, the cells were incubated with the following 6 groups (each group included 3 wells): (1) Control (PBS) (2) IMs (3) CIMs (4) IMs+NIR (5) TIMs+NIR (6) CIMs+NIR. The IR780 concentration was 50 µg/ml in groups 2, 3, 4, 5 and 6. After 2 h incubation, the culture medium was refreshed to eliminate the suspended nanoparticles. Then, the cells in groups 4, 5 and 6 were irradiated by an 808 nm laser (0.6 W/cm^2, 5 min). After treatment, cells were treated with LIVE/DEAD Viability/Cytotoxicity Kit according to the protocol and observed under a fluorescent microscope (IX81, Olympus, Japan).

The efficacy of phototherapy with various doses of CIMs in SK-HEP-1 and Huh7 cells under illumination was also tested. Cells were first cultured into a 6-well plate for 24 h. Various concentrations (0.50, 1.00, and 2.00 mg/mL) of CIMs were added into the cells, respectively. After 24 h, the treated 6-well plates were washed by PBS and then exposed to 808 nm wavelength laser irradiation (0.6 W/cm^2) for 5 min. The viability of HCC cells was investigated using the Annexin V-FITC/PI Apoptosis Kit (Multi Sciences, China) and quantified by a flow cytometer.

**In vivo systemic toxicity, bio distribution and tumor imaging**

All animal procedures in this study were performed according to the Institutional Animal Care and Use Committee at Wuhan University. For toxicity assessment, BALB/c-nu mice were intravenously injected with saline, IR780, IMs, and CIMs (4.5 mg/kg of IR780) twice every 3 days. At 19 days post-injection, the mice were killed, and the main organs including heart, liver, spleen, lung, and kidneys were collected and fixed into formalin for the paraffin embedding and sectioning. The organs were then stained with hematoxylin and eosin (H&E) to evaluate toxicity by histopathology.

For the subsequent studies, 5×10^6 Huh-7 cells
were subcutaneously injected into the flanks of 5-week old male BALB/c-nu mice. When tumors reached the size of ∼100 mm³, saline, IR780, IMs, and CIMs (1.5 mg/kg IR780) were intravenously (i.v.) injected into the mice (n = 5). At 24 h post-injection, fluorescent images were collected using an in vivo imaging system (Bruker Xtreme, USA) with 704 nm excitation wavelength.

For biodistribution assay, 150 µl free IR780, IMs and CIMs (1.5 mg/kg IR780) were intravenously injected when the tumor size reached about 100 mm³. The mice were killed at 12, 24 and 48 h post-injection to extract various tissues including the heart, liver, spleen, lung, kidney and tumor. To determine the contents of IR780, the tissues were further homogenized, and 2.5 mL methanol was added to extract IR780. The concentration of IR780 was then determined using fluorescence spectroscopy.

Antitumor effect in vivo

To test the in vivo antitumor effect, 5×10⁶ Huh-7 cells were subcutaneously injected into the flanks of 5-week old male BALB/c-nu mice. The mice were divided randomly into 5 groups (each group included 5 mice): (1) Control (saline) (2) IMs (3) CIMs (4) IMs+NIR (5) CIMs+NIR. The IR780 dosage was 1.5 mg/kg in groups 2, 3, 4 and 5. Saline and various nanomaterials were injected intravenously. After 24 h post-injection, the tumor sites of mice in groups 4 and 5 were irradiated by an 808 nm laser (0.6W/cm², 5 min). This procedure of administration and irradiation was conducted every 3 days for 19 days. Thermographic images were taken by an infrared thermal camera (A150-15-M, Irtech Ltd.), and the photothermal temperatures at various times were recorded. Animal weight and tumor volume were recorded every 3 d until the end of the experiment. Tumor volume (V) was calculated by the formula: V = (Length × Width²)/2. On the 19th day of the administration period, mice were euthanized by asphyxiation and the tumors were then extracted for terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining.

Statistical analyses

The data were presented as mean values ± SD and each value represented the mean of at least three repetitive experiments in each group. Non-parametric test was performed using GraphPad Prism 7.0 to assess the significance of the difference between two groups, *p < 0.05 and **p < 0.01.

Results and Discussion

Construction of CAR-T cells and their ability to target GPC3 positive HCC cells

Blood derived T cells were separated and activated with CD3 and CD28 for 48 h, and transduced with GPC3-CAR lentivirus. At day 14 post-transduction, flow cytometry results showed transduction efficiencies of approximately 81-86 % (Figure 2B). The T cell population after the construction of CAR-T cells which was similar between T cells and CAR-T cells (Figure S1A). Next, LDH assays were performed to assess the cytotoxicity of GPC3-CAR-T cells. The T cells or CAR-T cells were co-cultured with GPC3 over expressing HCC cells (Huh-7 cells) or GPC3 under expressing HCC cells (SK-HEP-1 cells) (shown in Figure S1B and C) at different E: T ratios (1:1, 1:4, 1:8). In this process it was apparent that GPC3-CAR-T cells were much more cytotoxic to Huh-7 cells than SK-HEP-1 cells (Figure 2C), and the T cells did not show significant cytotoxicity to either HCC cell groups. The CAR-T cells and T cells proliferation at different time point, day 1, day2 and day 4 after the treatment of CFSE reagent (Figure 2D). The proliferation rate of CAR-T cells was obviously enhanced compared with T cells. The high proliferation ability of CAR-T cells was caused by the intracellular costimulatory molecules, CD28 and CD3ζ which were the components of CAR structure. It proved the successful construction of CAR-T cells. These findings indicated that the genetically modified CAR-T cells could precisely target GPC3 positive HCC cells in contrast to normal T cells.

Preparation and Characterization of CIMs

Transmission electron microscope (TEM) was used to observe the morphology of IMs and CIMs. As seen from the TEM images in Figure 3A and Figure S2A, the size of CIMs (about 110 nm) was larger than that of IMs (about 95 nm), and the thickness of the CAR-T layer was almost 5 nm. Threshold levels of protein content in various nanoparticles were determined by SDS-PAGE and western blot, as illustrated in Figure 3B and 3C. The results indicated the difference in protein content between TV and CV. More importantly, similar protein content was found in CV and CIMs, while almost zero protein content was in the band of IMs. These results indicate the successful translocation of the CAR-T membrane proteins from cells to IMs. As shown in Figure 3D, the mean zeta potential of CVs and CIMs were −6.7 mV, which were higher than that of IMs (−11 mV). The negative charge of CAR-T vesicle surface caused the change in zeta potential. As seen from
Figure 3E, the average hydrodynamic diameters of IMs (particle size distribution from 68 nm to 142 nm, PDI=0.135), TIMs (particle size distribution from 79 nm to 142 nm, PDI=0.262), CIMs (particle size distribution from 91 nm to 164 nm, PDI=0.288) and CVs (particle size distribution from 106 nm to 345 nm, PDI=0.326) were 105 nm, 122 nm, 135 nm and 201 nm, respectively. The hydrodynamic diameter and zeta-potential results show that CAR-T and T vesicles successfully coated the nanoparticles. The IR780 loading content (DLC) and loading efficiency (DLE) in the experiment were 31.8±3.2 % and 94.2±3.6 %, respectively, (Figure 3F) indicating the high drug loading capacity of CIMs. As shown in Figure S2B, IR780 and IMs had strong absorption at 780 nm. On the other hand, TIMs and CIMs showed obvious red shift and the maximum absorption peak was around 800 nm, which was possibly caused by membrane wrapping. The results of in vitro drug release experiments showed that the release rate in IMs without membrane coating was very fast (Figure S2C), while the release rate of IR780 in TIMs and CIMs was significantly slowed down. This indicates that the membrane coating was beneficial to improve the problem of sudden or instantaneous release. During the experiments, IR780 was found to degrade rapidly under light (Figure S2D and E), so drug release experiments under radiation were not designed. The above results were consistent with previously reported research [28]. To verify the right orientation of membrane proteins after the cell membrane coating on IMs, CD3 was quantified by flow cytometry on CIMs surface and comparing with that on CAR-T cells membranes with an equal amount of membrane proteins. No significance was detected in CD3 level between CIMs surface and CAR-T cells membranes (Figure S2F). As membrane coating on CIMs was derived from the CAR-T cell membrane, this result indicated the right-side-out protein which meant the right ScFv extending from the surface of CIMs. In addition, thermal imaging showed the excellent photothermal conversion of IR780, as illustrated in Figure 3G-H. The IMs and CIMs exhibited similar temperatures after being exposed to NIR irradiation for 5 min, showing that the cell membrane coating had insignificant influence on the photothermal ability of IR780. The temperature of nanoparticle-free phosphate buffer solution (PBS) did not increase. Then photothermal conversion efficiency of CIMs is 22.2 % (Figure S2G and H). The superior photothermal conversion of IR780 enables it to destroy cancer cells via hyperthermia (42–47 °C) [34].
Evaluating of the targeting ability and biocompatibility of CIMs

The Huh-7 cells were cultured with the same quantity of IMs and CIMs nanoparticles, and IR780 fluorescent signal (700-800 nm) was detected by CLSM at an excitation wavelength of 633 nm. The cells treated with CIMs exhibited bright red fluorescence, and the number of CIMs bound to cells was dramatically increased compared with other nanoparticles (Figure 4A and B). These results demonstrate the ability of CIMs to target cancer cells in vitro. The mean IR780 fluorescence intensity in each group was further determined by flow cytometry (Figure S2I). The results showed that the fluorescence intensity of the CIMs group was 10 and 100 times higher than that of the IMs and IR780 groups, respectively. It was also much higher than that of TIMs. This result indicates that more nanomaterials targeted the tumor cells in the CIMs group, and that CIMs have more robust targeting ability than IMs and IR780. Previous studies have found that IR780 was retained in the mitochondria of cancer cells [35]. Thus, it is not unexpected to see higher tumor targeting in IR780 and IMs groups when compared to the control. It is worth noting that T cell membrane has a variety of proteins on its surface to detect inflammation and diseased tissues [36, 37], while CAR-T cells are manufactured with tumor targeting ability compared to their native counterparts.

Therefore, by coating the novel nanomaterials with CAR-T membranes, their targeting ability was inherited by the nanomaterials. Then, the nanoparticle uptake by Huh-7 cells was quantitatively analyzed with various incubation time periods at the initial IR780 concentration of 50 μg/ml. As shown in Figure S2J, IR780 content in cells in the CIMs group increased the most rapidly, which was also due to its excellent tumor cell targeting ability.
Biocompatibility of nanomaterials is a necessary precondition for biomedical applications [38]. To investigate the biocompatibility of the CIMs, flow cell death assays were performed on normal liver L02 cells. Figure 4C shows the viability of cells cultured with CIMs at various concentrations in comparison with untreated controls. Even at relatively high concentrations (2 mg/mL) of CIMs, the cell survival rate is over 90%, demonstrating good biocompatibility and safety towards normal cells. In addition, due to the weak targeting ability of CIMs for normal cells, the apoptosis rate of L02 cells was also very low under NIR treatment.

**In vitro phototherapy**

*In vitro* photothermal therapy was carried out on Huh-7 cells. The results of CCK-8 (Figure 5A) showed a high survival rate for tumor cells treated with different nanoparticles. In the IMs + NIR, TIMs+NIR and CIMs + NIR groups, the survival rate of cells was rapidly reduced over time to 50%, 39% and 17% at 24 hours, respectively. Similar results also be proved by flow cytometry assays in Figure S3A. This finding indicates the high hyperthermic cytotoxicity of IR780. In addition, it shows that CIMs were more effective than IMs and TIMs, and that the CAR-T membrane provided better targeting towards tumor cells and antitumor effects. A live/dead cell staining kit was also used to directly observe cell death. As illustrated in Figure 5B, PBS and IMs treated cells showed bright FDA green fluorescence, indicating high survival rate. IMs + NIR, TIMs + NIR and CIMs + NIR treatments resulted in low survival rates, with CIMs + NIR being more effective. This result was consistent with the
CCK-8 result. Besides, the specific targeting ability and NIR-induced tumor killing ability of CIMs were confirmed on GPC3 overexpressed SK-HEP-1 cells (Figure 5C-D). As the upregulation of GPC3 protein on SK-HEP-1 cells which was GPC3 negative (Figure S2K), the targeting ability of CIMs was better performed. While, no significance was observed on TIMs. Overall, the results demonstrate that CIMs have superior antitumor effects.

**In vivo antitumor effect**

The antitumor ability of CIMs was studied in mice under a subcutaneous liver cancer model. As shown in Figure 6A, when the tumor was exposed to laser irradiation for 5 min, IMs and CIMs groups experienced a significant temperature rise of 15 °C, with the final temperature reaching more than 50 °C. Such temperatures are sufficient for hyperthermic killing of tumor cells. In the saline group, the temperature rose to only 40 °C, which is not high enough to kill cells. The temperature was then monitored at regular intervals over a period of 5 min, and a temperature curve was generated (Figure 6B). The temperatures of CIMs and IMs groups rose quickly in the first 2 min, indicating good thermal conversion efficiency of IR780. In addition, CIMs
resulted in higher temperatures than IMs, confirming that CIMs were specifically enriched in tumor tissues, resulting in an enhanced photothermal effect. Changes in tumor volume and weight were also observed (Figure 6C and E). In the saline and IMs groups, the tumor tissue grew rapidly. When IMs or TIMs were injected and the tumor was irradiated, the tumor volume was reduced by 50%, indicating the ability of IMs and TIMs to induce tumor cell death via a photothermal effect. In the CIMs+NIR group, the tumor volume was further reduced compared with IMs+NIR and TIMs+NIR, demonstrating the enhanced localization from the CAR-T membrane coating. While, no significance was observed in tumor volume between IMs+NIR and TIMs+NIR. There was also no significant reduction in body weight for each group of mice, indicating that the material had no serious systemic toxicity (Figure S3B). Using TUNEL staining, the tumor inhibition was mechanistically associated with tumor death as illustrated in Figure 6F. No significant fluorescence or cell death was observed in the saline and IMs groups, while significant cell death was observed in CIMs+NIR and IMs+NIR groups, with CIMs+NIR showing maximal effect. Through the CLSM photos of distribution of IMs, TIMs and CIMs in tumor, the red fluorescence signal for IR780 was stronger for CIMs relative to IMs or TIMs (Figure S3C), indicating enhanced tumor targeting ability of CIMs in vivo.

**In vivo tumor imaging, biodistribution, and systemic toxicity assessment**

Near-infrared fluorescence tumor imaging was carried out on the Huh-7 subcutaneous hepatocellular carcinoma model. As shown in Figure 7A, at 24 h post-injection, the CIMs group displayed the strongest fluorescence signal at the tumor site, while IR780 and IMs groups exhibited weaker fluorescence, indicating better targeting by CIMs. This finding also suggests that CIMs is an excellent material for...
near-infrared tumor imaging. The levels of IR780 in each organ and tumor tissue at 12-, 24- and 48 h post-injection were also analyzed, as seen in Figure 7B. As expected, the content of IR780 in tumor tissues for the CIMs group was much higher than that of the IMs and IR780 groups, which was consistent with the live imaging results and confirmed the superior targeting by CIMs. Normal nude mice were also used to study the side effects of the nanoparticles on internal organs (Figure 7C). After H&E staining of the main organs (heart, liver, spleen, lung, and kidney), no obvious organ damage was observed, indicating that CIMs have excellent biocompatibility in vivo, and no short-term side effects.

Discussion

The CAR, which is based on the T cell receptor, is an artificially modified fusion protein which contains an extracellular antigen recognition domain fused to various intracellular signaling domains. In most cases, the extracellular domain is the single-chain variable region (ScFv) of monoclonal antibody heavy and light chains which can directly recognize the TAA on tumor cell surface without the presentation from MHC molecules [39]. The intracellular domains include CD3ζ, CD28, 4-1BB, or OX40, and are devised to enhance the activation of T cells [39]. When CAR-T cells identify tumor cells expressing the target TAA on a cell surface, T cell activation, proliferation, cytokine secretion, and cytotoxicity toward TAA-expressing tumor cells are triggered. The field of CD19-targeting CAR-T cell therapy has experienced dramatic progress in hematological cancers such as acute lymphoblastic leukemia [40].

However, CAR T cells face a unique set of challenges in the field of solid tumors [41]. To achieve a favorable clinical outcome, CAR T cells have to overcome a series of increasingly arduous barriers. First, the specific antigens which are expressed should be able to clearly demarcate the tumor from normal tissue. Then, CAR-T cells should be able to find and penetrate the desmoplastic stroma that surrounds the tumor. Once the cells are within the tumor, they must expand, persist and mediate cytotoxicity in a hostile milieu largely composed of immunosuppressive...
modulators [41, 42]. While a seemingly herculean task, all the above requirements can potentially be surmounted effectively through intrinsic or extrinsic modifications of CAR-T cells.

The application of nanotechnology in medicine is providing significant opportunities and new perspectives for novel and effective treatments in many diseases. Nanomedicine can be defined as the design and development of therapeutics and diagnostic agents in the nanoscale range (with diameters ranging from 1 nm to 1,000 nm), with the possibility to move within biological systems, and transport and deliver a variety of biomedical entities for the treatment, prevention, and diagnosis of many diseases [43]. Due to their unique characteristics, including large surface area, structural properties, and long circulation time in blood compared with small molecules, nanoparticles have emerged as attractive candidates for optimized therapy through personalized medicine [44, 45].

Attempts have been performed on the combination of nanomedicine and cell therapy, especially T cell therapy. Rachel A Burga et al. generated a biohybrid nano-immunotherapy using antigen-specific T cells as vehicles for Prussian blue nanoparticles (PBNPs). They conjugated PBNPs onto primary EBV antigen-specific cytotoxic T lymphocytes (CTL) and the conjugation process maintained the individual functions of both the PBNPs and the CTL. These studies suggest the potential use of our biohybrid CTL:PBNPs as a therapeutic for the treatment of cancer [46]. Matthias T. Stephan et al. used the method of conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells to provide sustained pseudo-autocrine stimulation to donor cells. Dramatic enhancements in tumor elimination in a model of adoptive T-cell therapy for cancer were detected and increased the in vivo repopulation rate of hematopoietic stem cell grafts, using very low doses of adjuvant drugs that were ineffective when given systemically [47]. These works could be proof of concept study demonstrating the feasibility of the application of nanoparticles on T cell therapy. The synthetic polymer poly (ethylene glycol) (PEG) which they used could create a hydration layer, while also providing steric stabilization lead to a stealthy nanoparticle surface that interacts less with its environment, enabling significantly enhanced blood circulation. A wide range of ligands, including antibodies, aptamers, peptides, and small molecules, to add targeting functionality. It has been proven that PEG was effective at minimizing nonspecific interactions in complex media, however, increasing reports about immune response against the synthetic polymer and the antibodies against PEG can potentially impact performance over multiple administrations, let alone the difficulties for large-scale manufacturing of bottom-up targeting ligand conjugation strategies [48, 49].

Cell membrane-coated nanoparticles, characterized by a synthetic nanoparticle core cloaked by a layer of natural cell membrane, inherently mimic the properties of the source cells from which their membrane is derived, and thus exhibit a wide range of functions such as long circulation and disease-relevant targeting [50]. Different types of membrane coatings with special features are currently employed, such as red blood cells (RBCs) membranes, cancer cell membranes and platelet membrane membranes [51-53]. Their advantages for specific applications are covered in depth, which uniquely benefit from the presence of biological membranes. A layer-by-layer hybrid nanoparticles has been designed, which enabled the release of IR-780 dye for NIR-induced photothermal and photodynamic effects, and the release of imatinib-loaded glucocorticoid-induced TNF receptor family-related protein/poly(lactic-co-glycolic acid) (GITR-PLGA) nanoparticles to initiate antitumor immunotherapy. The photothermal and photodynamic effects caused by IR-780 under NIR exposure resulted in direct tumor apoptosis/necrosis and the production of tumor-associated antigen, promoted dendritic cell maturation, and enhanced the presentation of tumor-associated antigen to T cells, while the imatinib-loaded GITR-PLGA cores reduced the suppressive function of Treg cells, and consequently activated effective CD8+ T cells towards tumors [54]. Lianru Zhang et al. reported a biomimetic delivery platform based on human cytotoxic T-lymphocyte membranes camouflaged poly-lactic-co-glycolic acid nanoparticles. This drug-delivery platform retained both the long circulation time and tumor site accumulation ability of human cytotoxic T lymphocytes [55]. This indicated, coating with CTL cell membranes could gift tumor targeting ability to nanoparticles. While, as we all known, the gene-engineered CAR-T cells obtain enhanced specific tumor targeting ability in comparison with T cells. Therefore, it inspired us to use CAR T membrane coated nanoparticles for targeted tumor!therapy.

In this study, the outstanding targeting ability of CAR-T cells was recruited along with the photothermal ability and advantage in drug delivery of nanoparticles by cell membrane coating method. By coating with the membranes of GPC3-specific CAR-T cells, the novel nanoparticles, CIMs, could inherent the targeting ability and be bestowed with a long circulation. First, we designed and constructed the
GPC3 specific CAR-T cells by lentivirus transfection. Through the verification of the enhanced T cell proliferation and cytotoxicity towards GPC3+ HCC cells, the unique characteristics of CAR-T cells were confirmed which indicated the successful construction of GPC3 specific CAR-T cells (Figure 2). Next, membranes of CAR-T cells and T cells were isolated and coated onto IR780 loaded meso-porous silica nanoparticles to construct different novel nanoparticles (Figure 3), which were then thoroughly characterized, like zeta potential and hydrodynamic diameters. The larger size of CIMs was observed by TEM. The right membrane proteins content and orientation were also confirmed which indicated the right ScFv extending from the surface of CIMs and further guarantee of tumor targeting ability inherited from CAR-T cells. The photothermal potential of these novel nanoparticles was also confirmed. IR780 contained CIMs had strong absorption at around 800nm. Coating with the membranes could slow down the release rate of IR780 and stabilize the CIMs but didn’t impair the photothermal conversion of IR780. Furthermore, the results of in vitro and in vivo experiments were then conducted to illustrate the enhanced tumor targeting ability, minimal systematic toxicity, and excellent photothermal response of the novel photothermal therapeutic agent. These findings indicate that novel CAR-T cell membrane-coated nanoparticles can be developed for cancer therapy in the future.

Acknowledgements

Our work was supported by National Natural Science Foundation for Outstanding Youth Foundation (Grant No. 61722405), National Key R&D Program for Major Research Instruments (Grant No. 81527801), National Key R&D Program (Grant No. 2016YFC1000700), Hubei Province health and family planning scientific research project (WJ2017Z007) and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund, Project znpy2017026.

Supplementary Material

Supplementary materials and methods, figures. http://www.thno.org/v10p1281s1.pdf

Competing Interests

The authors have declared that no competing interest exists.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
2. Dhir M, Melin AA, Doualher J, Lin C, Zhen WK, Hussain SM, et al. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016; 263: 1112-25.
3. Sun YF, Guo W, Xu Y, Shi YH, Gong ZJ, Ji Y, et al. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Clin Cancer Res. 2018; 24: 547-59.
4. Gao XH, Tian L, Wu J, Ma XL, Zhang CY, Zhou Y, et al. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2017; 47: 1001-71.
5. Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Anticancer Platelet-Mimicking Nanovehicles. Adv Mater. 2015; 27: 7043-50.
6. Gao W, Hu CM, Fang RH, Luk BT, Su J, Zhang L. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater. 2013; 25: 3549-53.
7. Zhai Y, Su J, Ran W, Zhang P, Yin Q, Zhang Z, et al. Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy. Theranostics. 2017; 7: 2575-92.
8. Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W, et al. Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors. Adv Mater. 2016; 28: 9581-8.
9. Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W, et al. Cancer Cell Membrane-Coated Gold Nanocages with Hyperthermia-Triggered Drug Release and Homotypic Target Inhibit Growth and Metastasis of Breast Cancer. Adv Funt Mater. 2016; 27: 1604300.
10. Fang RH, Hu CM, Chen KN, Luk BT, Carpenter CW, Gao W, et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale. 2013; 5: 8884-8.
11. Hu CM, Zhang L, Aryal S, Cheng C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011; 108: 10980-5.
12. Xuan M, Shao J, Dai L, He Q, Li J. Macropage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In vivo Cancer Therapy. Adv Healthc Mater. 2015; 4: 1645-52.
13. Hu CM, Fang RH, Wang KC, Luk BT, Thampihiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015; 526: 118-21.
14. Rao L, Bu LL, Cai B, Xu JH, Li A, Zhang WF, et al. Cancer Cell Membrane-Coated Upconversion Nanoprobes for Highly Specific Tumor Imaging. Adv Mater. 2016; 28: 3460-6.
15. Rao L, Meng Q-F, Huang Q, Wang Z, Yu G-T, Li A, et al. Platelet-Leukocyte-Membrane-Coated Immunomagnetic Beads for Highly Efficient and Highly Specific Isolation of Circulating Tumor Cells. Adv Funct Mater. 2018; 28: 1803311.

16. Rao L, Cai B, Bu LL, Liao QQ, Guo SS, Zhao XZ, et al. Microfluidic-Fluidic-Partner-Selectionsynthesis of Drug-responsive and Drug-coated Magnetic Nanoparticles for Enhanced Imaging-Guided Cancer Therapy. ACS Nano. 2017; 11: 5406-505.

17. Rao L, Wang W, Meng QF, Tian M, Cai B, Wang Y, et al. A Biomimetic Nanodecoy Traps Zika Virus To Prevent Viral Infection and Fetal Microcephaly Development. Nano Lett. 2019; 19: 2125-22.

18. Grupp SA, Kaldjian K, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509-18.

19. Brettens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118: 4817-28.

20. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maris J, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709-20.

21. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015; 33: 1688-96.

22. Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, et al. Regional CAR-T cell infusions for peritonel carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016; 23: 142-8.

23. Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016; 59: 468-79.

24. Dargel C, Bassani-Stemberg M, Hasreiter J, Zani F, Röckmann JH, Thielle F, et al. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In vitro and in vivo. Mice. Gastroenterology. 2015; 149: 1042-52.

25. Gao H, Li K, Tu H, Han X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014; 20: 6418-26.

26. Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, et al. Anti-GP3-CAR-T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol. 2016; 7: 690.

27. Zhang C, Wang S, Xiao J, Tan X, Zhi Y, Su Y, et al. Sentinel lymph node mapping by a near-infrared fluorescent heptamethine dye. Biomaterials. 2010; 31: 1911-7.

28. Jiang C, Cheng H, Yuan A, Tang X, Wu J, Hu Y. Hydrophobic IR820 encapsulated in biodegradable human serum albumin nanoparticles for photothermal and photodynamic therapy. Acta Biomater. 2015; 14: 61-9.

29. Chen Y, Chen H, Shi J. In vivo bio-safety evaluations and diagnostic/diagnostic applications of chemically designed mesoporous silica nanoparticles. Adv Mater. 2013; 25: 3144-76.

30. Shao D, Li M, Wang Z, Zheng X, Luo YH, Chang Z, et al. Bisinspired Diselenide-Bridged Mesoporous Silica Nanoparticles for Dual-Responsive Protein Delivery. Adv Mater. 2018; e1801198.

31. Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Enhanced Blood Susceptibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Theranostics. 2017; 7: 525-37.

32. Ishiguro T, Sugimoto M, Kinosita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican-3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008; 68: 9832-8.

33. Lv S, Tang Z, Li M, Lin J, Song W, Liu H, et al. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials. 2014; 35: 6118-29.

34. Landry J, Samson S, Chretien P. Hyperthermia-induced cell death, thermotolerance, and heat shock proteins in normal, respiration-deficient, and glycolysis-deficient Chinese hamster cells. Cancer Res. 1986; 46: 324-7.

35. Wang X, Luo S, Wang D, Su Y, Cheng T, Shi C. A NIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Nanomedicine (Lond). 2009; 4: 249-52.

36. Tan X, Luo S, Wang D, Su Y, Cheng T, Shi C. A NIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Nanomedicine (Lond). 2017; 11: 1759-67.

37. Stephane MT, Moon JJ, Um SH, Bershstein A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010; 16: 1033-41.

38. Yang Q, Lai SK, Anti-PDG: immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7: 655-77.

39. Ishihara T, Takeda M, Sakamoto H, Kimo M, Kobayashi C, Takasaki N, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res. 2009; 26: 2270-9.

40. Fang RH, Kroll AV, Gao W, Zhang L. Cell Membrane Coating Nanotechnology. Adv Mater. 2018; 30: e1707859.

41. Luk BT, Fang RH, Hu CM, Cook IA, Thampihivatanag S, Debaini D, et al. Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors. Theranostics. 2016; 6: 1004-11.

42. Liu X, Sun Y, Xu S, Gao X, Kong F, Xu K, et al. Homotypic Cell Membrane-Coated Biocompatible Nanocarbon for the Targeted Chemotherapy of Hepatocellular Carcinoma. Theranostics. 2019; 9: 5028-38.

43. Liu J, Qu H, Wu D, Zhu C, Yang Y, Jin X, et al. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cell and tumor vasculature dual-targeting strategy. Theranostics. 2018; 8: 2683-95.

44. Ou W, Jiang L, Thapa RK, Soe ZC, Poudel K, Chang JH, et al. Combination of NLRVJ therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photomimetic. Theranostics. 2018; 8: 4574-90.

45. Zhang L, Li R, Chen H, Wei J, Qian H, Su S, et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int J Nanomedicine. 2017; 12: 2129-42.